Study Comparing Two Different Schedules of Radiation for Early-stage Lung Cancer

Lung Cancer Clinical Trial

Official title:

Three- Versus Five-Fraction Regimens of Stereotactic Body Radiotherapy for Peripheral Early-Stage Non-Small-Cell Lung Cancer: A Prospective Randomized Phase II Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03706027
• Other study ID #: 72835
• Status: Recruiting
• Phase: N/A
• Start date: December 15, 2018
• Est. completion date: November 15, 2025

Study information

• Verified date: March 2024
• Source: University of Rochester
• Contact: Deepinder Singh, MD
• Phone: 585-275-5623
• Email: deepinder_singh[@]urmc.rochester.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study's goal is to find out if the kind of side effects people experience from radiation is different depending on the schedule of their radiation treatment. Patients will be randomly assigned to either the 3 Fraction or 5 Fraction schedule of radiation. After patients complete radiation treatment, they will follow up with their radiation oncologist.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: November 15, 2025
• Est. primary completion date: November 15, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histological confirmation of non-small cell cancer will not be required as primary goal of this phase II trial is to look at toxicity. However, all primary non-small cell lung cancers otherwise of following types are eligible: squamous cell carcinoma, adenocarcinoma, large cell carcinoma, bronchioalveolar cell carcinoma, or non-small cell carcinoma not otherwise specified.

• Eligible patients must have appropriate staging studies identifying them as specific subsets of AJCC stage I or II based on only one of the following combinations of TNM staging:

• T1, N0, M0

• T2 (= 5 cm), N0, M0

• Patients with hilar or mediastinal lymph nodes = 1cm and no abnormal hilar or mediastinal uptake on PET will be considered N0. Patients with > 1 cm hilar or mediastinal lymph nodes on CT or abnormal PET (including suspicious but non-diagnostic uptake) may still be eligible if directed tissue biopsy of all abnormally identified areas are negative for cancer. All patients with suspicious nodes will be evaluated for mediastinal and hilar staging with bronchoscopy and (if amenable) bronchoscopic biopsy (preferably navigational biopsy and/or endobronchial US guided biopsy).

• Zubrod performance status 0-2 within 4 weeks of study entry.

• Women of childbearing potential and male participants must use an effective contraceptive method.

• Evaluations required at time of study entry:

• History & Physical by a radiation oncologist within 4 weeks of study entry;

• Vitals within 4 weeks of study entry;

• Evaluation by a thoracic surgeon (either via clinical examination and/or input at multidisciplinary tumor board) prior to study entry;

• PFTs: Routine spirometry, lung volumes, diffusion capacity, and arterial blood gases within 8 weeks prior to study entry;

• CT Chest within 6 weeks of study entry (preferably with intravenous contrast, unless medically contraindicated) - to include the entirety of both lungs, the mediastinum, liver, and adrenal glands; primary tumor dimension will be measured on this CT;

• Whole body positron emission tomography (PET) scan using FDG with adequate visualization of the primary tumor and draining lymph node basins in the hilar and mediastinal regions within 6 weeks prior to study entry.

• Informed consent signed by the subject and a member of the study team.

Exclusion Criteria:

• Patients with central tumors. Specifically; central location implies a tumor inside the zone of the proximal bronchial tree defined as a volume 2 cm in all directions around the proximal bronchial tree (carina, right and left main bronchi, right and left upper lobe bronchi, intermedius bronchus, right middle lobe bronchus, lingular bronchus, right and left lower lobe bronchi

• Evidence of regional or distant metastases after appropriate staging studies.

• Synchronous primary NSCLC.

• Those with prior malignancy in the past 2 years other than non-melanomatous skin cancer or in situ cancer or thyroid cancer.

• Previous lung or mediastinal radiotherapy.

• Plans for the patient to receive concomitant antineoplastic therapy (including standard fractionated radiotherapy, chemotherapy, biological therapy, vaccine therapy, and surgery) while on this protocol.

• Patients with active systemic, pulmonary or pericardial infection.

• Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus.

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Intervention

Device:
• radiation therapy-3 fractions
Radiation therapy given in a 3 fraction schedule (over 3 days). Total dose is 54 Grays.
• Radiation therapy-5 fractions
Radiation therapy given in 5 fractions (over 5 days). Total dose is 60 Grays.

Locations

Country	Name	City	State
United States	James P. Wilmot Cancer Center at University of Rochester Medical Center	Rochester	New York

Sponsors (1)

Lead Sponsor	Collaborator
University of Rochester

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	frequency of grade 3 treatment related toxicities or higher	Toxicities will be assessed using the National Cancer Institute common toxicities criteria version 4.0. The rates of grade 3 or higher adverse events at 1 year will be calculated as the proportion of patients who have any adverse event of interest by the end of year 1 among the total analyzable patients in each arm.	1 year
Secondary	mean survival time of patients with overall survival	The failure event for overall survival is a death due to any cause. Survival time is measured from the date of randomization to the date of death or last follow up.	3 years
Secondary	proportion of patients with disease-free survival	The failure event for disease-free survival is defined as death due to any cause, local failure, marginal failure, involved node failure, regional failure, distant metastasis, or second primary.	3 years
Secondary	proportions of patients with primary tumor control	Marginal failures will be considered events for primary tumor failure. The primary tumor control rate at 1 year will be calculated as the number of patients who do not have a local progression event by the total number of analyzable patients in each arm at 1 year.	3 years